Format

Send to

Choose Destination
J Surg Oncol. 1994 Jul;56(3):146-52.

High proliferative rates demonstrated by bromodeoxyuridine labeling index in breast carcinomas with p53 overexpression.

Author information

1
Dept. of Pathology, St. Luke's Hospital, Chesterfield, MO 63017.

Abstract

The protein p53 is a product of a suppressor oncogene. Mutations occurring in 13-15% of breast carcinomas are associated with p53 stainability within nuclei and progression of the tumor. We determined the extent to which p53 abnormality was associated with proliferation by measuring p53 immunohistochemically with a polyclonal antibody and monoclonal PAb1801 in invasive carcinomas of known S-phase fraction (SPF) assessed histologically by bromodeoxyuridine incorporation. Results with the two antibodies always agreed. One of 20 low, 2/18 midrange, and 9/17 high SPF carcinomas were positive for p53. P53 positivity was also related to other indicators of aggressiveness including size of primary tumor, nuclear and nucleolar size, and estrogen and progesterone receptor content, but relationships between p53 and vascular invasion and lymph node metastasis were not found. We conclude that nuclear p53 accumulation is more closely related to proliferation than to invasion and metastasis, and that it identifies some but not all breast carcinomas with high proliferative indices.

PMID:
8028344
DOI:
10.1002/jso.2930560304
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center